# Sensorium Therapeutics

> Sensorium Therapeutics is a Boston-based biotechnology company building first-in-class central nervous system (CNS) medicines by decoding nature's neuroactive chemistry with AI. Founded out of Massachusetts General Hospital and Harvard, its proprietary SensAI platform mines more than 50 million curated relationships across ethnopharmacology, chemistry, pharmacology, and clinical outcomes to identify de-risked starting points for new drugs. Its lead program, SNTX-2643, is a rapid-acting precision serotonin modulator for anxiety that received FDA IND clearance in 2025.

- **Founded:** 2021
- **Headquarters:** Boston, United States
- **Founders:** Jacob Hooker (CEO & Co-Founder), Stephen Haggarty (Scientific Co-Founder), Jerrold Rosenbaum (Scientific Co-Founder), Alex Simon (Co-Founder)
- **Team size:** About 27 employees
- **Products:** SensAI Platform, SNTX-2643 (SENS-01), SENS-03, SENS-08
- **Notable:** Advanced three CNS programs in under three years, FDA IND clearance for SNTX-2643, a first-in-class rapid-acting anxiolytic (July 2025), Raised approximately $64M in total funding

## Products & services

- **SensAI Platform** — Proprietary AI discovery engine integrating 700K+ natural product structures, 100K+ plants with 250K+ historical references, 1M+ bioassays, and 50M+ curated data relationships across ethnopharmacology, chemistry, pharmacology, neuroscience, and clinical outcomes to identify de-risked drug starting points.
- **SNTX-2643 (SENS-01)** — Lead program: a first-in-class, rapid-acting precision serotonin modulator for social anxiety disorder, differentiated from SSRIs. FDA IND cleared July 2025; first-in-human dosing in Q3 2025. Potential expansion to GAD, OCD, and PTSD.
- **SENS-03** — Preclinical candidate for drug-resistant epilepsy, targeting mechanisms distinct from currently approved antiseizure medications. Development candidate selection planned for 2H 2026.
- **SENS-08** — Early-stage program for cognitive dysfunction in neurodegenerative disease/Alzheimer's, supported by a $3.5M NIH award.

## Achievements

- Advanced three CNS programs in under three years
- FDA IND clearance for SNTX-2643, a first-in-class rapid-acting anxiolytic (July 2025)
- Raised approximately $64M in total funding
- Built SensAI platform spanning 50M+ curated biological data relationships
- Secured $3.5M NIH award for Alzheimer's cognition program (SENS-08)

## Latest updates

- **2025-08** — Raised $25M Series A extension led by new investors including Mission BioCapital and Hatteras Venture Partners.
- **2025-07** — Received FDA IND clearance for SNTX-2643, its first-in-class rapid-acting anxiolytic.
- **2025-09** — Began first-in-human (Phase 1) dosing of SNTX-2643.
- **2022-11** — Closed $30M Series A led by Santé Ventures to advance its nature-inspired discovery engine.

## Links

- Website: https://www.sensorium.bio/
- LinkedIn: https://www.linkedin.com/company/sensorium-therapeutics

---

Profile page: https://yespress.io/sensorium-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-12